This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| PSG1 | |
|---|---|
| Name | Pregnancy-specific beta-1-glycoprotein 1 |
| Uniprot | P11464 |
| Organism | Homo sapiens |
| Gene | PSG1 |
| Location | 19q13.2 |
PSG1
Pregnancy-specific beta-1-glycoprotein 1 is a member of the carcinoembryonic antigen family of immunoglobulin superfamily proteins expressed during human gestation. First characterized in studies of human placental secretome, PSG1 is secreted by syncytiotrophoblasts and detected in maternal serum, placenta preparations, and amniotic fluid. PSG1 has been investigated in relation to placental development, maternal-fetal tolerance, and as a biomarker in obstetric studies involving institutions such as World Health Organization, Harvard University, Stanford University, Oxford University.
The PSG1 gene is located on chromosome 19 within a cluster of related genes that includes PSG2 through PSG11 and other carcinoembryonic antigen family members such as CEACAM1 and CEACAM5. The PSG1 transcript encodes a preproprotein comprising an N-terminal signal peptide, an N-domain structurally related to immunoglobulin V-set folds, and two C2-set domains; the mature protein is approximately 40–45 kDa after glycosylation. PSG1 contains multiple N-linked glycosylation sites documented in proteomic maps produced by groups at European Molecular Biology Laboratory and National Institutes of Health. The PSG1 promoter region bears CpG-rich segments studied by laboratories at Max Planck Society and characterized in chromatin immunoprecipitation experiments reported from Cold Spring Harbor Laboratory. Structural comparisons have leveraged crystallographic and modeling platforms used by Protein Data Bank investigators.
PSG1 expression is highly placenta-specific, with transcription initiated in trophoblast lineages of the developing chorionic villi; expression kinetics were profiled by teams at Karolinska Institutet and University of Cambridge. Maternal serum PSG1 concentrations rise across gestation and peak in the third trimester, paralleling data from obstetric cohorts at Mayo Clinic, Cleveland Clinic, and Mount Sinai Health System. Regulation of PSG1 involves promoters responsive to placental transcription factors including GATA3, TEAD4, and TFAP2C, identified by reporter assays conducted at Johns Hopkins University and University of Pennsylvania. Epigenetic control via DNA methylation and histone modifications affecting PSG1 has been examined in studies affiliated with European Society of Human Genetics and clinical laboratories at Imperial College London.
PSG1 functions as an immunomodulatory and cell-adhesive glycoprotein in the maternal-fetal interface; mechanistic studies implicate interactions with leukocyte receptors, integrins, and extracellular matrix components characterized using assays developed at Scripps Research, Cold Spring Harbor Laboratory, and Weizmann Institute of Science. PSG1 modulates cytokine production in maternal immune cells, influencing levels of interleukins and transforming growth factor beta measured in experiments by investigators at National Institute of Child Health and Human Development and Vanderbilt University Medical Center. PSG1 also promotes trophoblast migration and invasion via signaling cascades involving focal adhesion kinases and MAPK pathways reported from University of Chicago and Karolinska Institutet. Ligand–receptor mapping has suggested PSG1 binds glycan-dependent receptors analogous to those characterized for CEACAM1 and SIGLEC family proteins in studies at University of Toronto and University of Oxford.
Altered PSG1 levels have been associated with obstetric complications including preeclampsia, intrauterine growth restriction, and preterm birth in clinical cohorts from National Health Service (England), Centers for Disease Control and Prevention, and tertiary centers such as Mount Sinai Hospital (Toronto). Low maternal PSG1 has been correlated with impaired trophoblast invasion in case-control studies from University College London and King's College London. Conversely, aberrant PSG1 expression is reported in certain malignancies, with tumor-associated expression investigated by groups at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. PSG1 has been explored as a prognostic biomarker and potential therapeutic target, with clinical assay development efforts involving companies and institutions such as Roche, Abbott Laboratories, and translational programs at NIH Clinical Center.
The PSG gene family expanded in primate lineages; comparative genomic analyses by teams at Broad Institute and Sanger Institute show lineage-specific duplications and divergence from ancestral CEACAM genes shared with species such as Pan troglodytes and Gorilla gorilla. Non-primate mammals lack direct orthologs but possess related carcinoembryonic antigen family proteins studied in rodent models at The Jackson Laboratory and Riken. Phylogenetic reconstructions using data from Ensembl and GenBank indicate positive selection in PSG N-domain residues, consistent with adaptive evolution in reproductive immunology highlighted by evolutionary biologists at University of California, Berkeley and University of Edinburgh.
Experimental reagents for PSG1 include recombinant proteins, monoclonal antibodies, and ELISA kits produced by academic and commercial providers such as Sigma-Aldrich, Thermo Fisher Scientific, and core facilities at Fred Hutchinson Cancer Research Center. In vitro models employ primary human trophoblasts, explant cultures, and trophoblast cell lines used by laboratories at University of Cincinnati and University of Washington; in vivo studies use humanized placental models and nonhuman primate research performed at centers including Yerkes National Primate Research Center. CRISPR/Cas9-mediated knockout and overexpression systems for dissecting PSG1 function have been implemented in collaboration with genomic cores at Wellcome Sanger Institute and Broad Institute. Proteomics and glycomics workflows to characterize PSG1 post-translational modifications utilize platforms from Massachusetts Institute of Technology and ETH Zurich.
Category:Human proteins